• Oil Edges Past $33 But Rising U.S.-China Tensions Cap Rally

    Oil Edges Past $33 But Rising U.S.-China Tensions Cap Rally(Bloomberg) — Oil traded near $33 a barrel as an escalating war of words between the U.S. and China added to caution over the prospects for a global recovery in demand.China warned on Sunday that some in the U.S. were pushing the countries toward a new Cold War, stoking concerns that deteriorating relations between Beijing and Washington could complicate the market’s recovery from a historic demand crash. Futures edged higher in New York after falling earlier, with trading volumes thin due to holidays in the U.S., U.K. and Singapore.See also: Oil’s Sudden Rebound Is Exposing the Achilles’ Heel of ShaleCrude has surged more than 75% this month and the boss of the International Energy Agency gave bulls further hope, saying in an interview that demand may well recover from an unprecedented shock caused by Covid-19. Even so, the return of U.S.-China tensions has soured risk sentiment and rekindled more-immediate demand concerns. There’s also concern that some supplies idled during oil’s rout will start to return.“With prices above $30, the recent rally may have pushed too far,” said Hans van Cleef, senior energy economist at ABN Amro. “Inventories remain highly elevated and every disappointment could trigger a fresh wave of profit taking. I will continue to point at downside risks towards my clients.”The U.S. should give up its “wishful thinking” of changing China, Foreign Minister Wang Yi said during his annual news briefing on the sidelines of National People’s Congress meetings in Beijing. He also warned America not to cross China’s “red line” on Taiwan.While fuel consumption climbs in some nations with the easing of lockdown restrictions, the cheapest U.S. gasoline in nearly two decades won’t be enough to entice nervous Americans to hit the road for Memorial Day weekend. The uncertainty around travel is so great due to the virus that American Automobile Association is not releasing a forecast for the first time in 20 years.“In the absence of strong government policies, a sustained economic recovery and low oil prices are likely to take global oil demand back to where it was, and beyond,” Fatih Birol, the head of the IEA, said in an interview, urging governments to focus spending on combating climate change.Big oil annual general meetings in the U.S. and Europe this week should shed light on how heavily producers have been hit by lockdowns, with Total SA, BP Plc, Exxon Mobil Corp. and Chevron Corp. among those fronting shareholders. Meanwhile, Russian President Vladimir Putin has given his government until June 15 to come up with a plan to support the country’s oil industry.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    from Yahoo Finance https://ift.tt/2zrg9KE

  • Lufthansa, German government agree on rescue package – source

    Lufthansa, German government agree on rescue package - sourceThe German government and the management of flagship carrier Lufthansa, which has been hit hard by the coronavirus pandemic, have reached an agreement on state aid worth billions of euros, a source close to the matter said. The agreement is still pending approval by the German coronavirus rescue fund’s steering committee, which is expected to meet on Monday, as well as Lufthansa’s boards and the EU commission. The German government declined to comment.

    from Yahoo Finance https://ift.tt/2XrKEbd

  • Bayer Reaches Deals on Large Portion of 125,000 Roundup Suits

    Bayer Reaches Deals on Large Portion of 125,000 Roundup SuitsMay.25 — Bayer AG has reached verbal agreements to resolve a substantial portion of an estimated 125,000 U.S. cancer lawsuits over use of its Roundup weedkiller, according to people familiar with the negotiations. Tim Loh reports on “Bloomberg Markets: European Open.”

    from Yahoo Finance https://ift.tt/2XxOvDY

  • Alibaba Drops After Projecting Slowing Growth in Uncertain Times

    Alibaba Drops After Projecting Slowing Growth in Uncertain Times(Bloomberg) — Alibaba Group Holding Ltd. slid after projecting revenue growth will slow this year, reflecting post-Covid 19 economic uncertainty at home as well as the potential for U.S.-Chinese tensions to disrupt its business.Its stock slid as much as 4% in Hong Kong Monday, after a drop of almost 6% in New York before the weekend. The e-commerce giant forecast sales growth this year of at least 27.5% to more than 650 billion yuan ($91 billion), down from 35% previously and slightly below analysts’ estimates. While it posted a better-than-expected 22% rise in March quarter revenue of 114.3 billion yuan, that marked its slowest pace of expansion on record.Online shopping began to bounce back from March, executives said Friday. But the tepid outlook demonstrates the world’s second-largest economy has yet to fully shake off Covid-19, with consumers still hesitant about spending on big-ticket items. Asia’s most valuable corporation is tackling also the rise of rivals such as ByteDance Ltd. and Pinduoduo Inc. And the Tmall operator is going head-to-head with Tencent Holdings Ltd. for internet leadership in everything from online media to payments and cloud computing. JD.com Inc., the No. 2 Chinese online retailer, forecast better-than-expected revenue this quarter.“The market is a bit disappointed despite the strength given 2Q guidance of 20-30% YoY growth for JD and 99% GMV growth in 1Q20 for PDD,” CICC analyst Natalie Wu wrote. “We regard Alibaba’s advantage as a market leader as intact and unchanged in the longer run, though it may take several quarters for market sentiment to swing back.”Read more: Alibaba Sales Growth Plumbs New Lows While Uncertainty EscalatesAlibaba has lost more than $70 billion of market value since the coronavirus first erupted in January, and now has to grapple with not just an uncertain global economic environment but also any potential fallout from U.S.-Chinese financial tensions. On Friday, executives sought to assuage concerns about a U.S. bill that mandates much closer accounting scrutiny of U.S.-listed Chinese companies and may bar them from American bourses.Chief Financial Officer Maggie Wu said Friday Alibaba’s financial statements have been consistently prepared in accordance with U.S. GAAP accounting measures and were beyond reproach. “The integrity of Alibaba’s financial statements speak for itself, we have been an SEC filer since 2014 and hold ourselves to the highest standard,” she told analysts on a conference call. “We will endeavor to comply with any legislation whose aim is to protect and bring transparency to investors who buy securities on U.S. stock exchanges.”The bigger short-term challenge is in reviving growth: Alibaba’s bread-and-butter customer management or marketing business grew just 3% in the March quarter. Much of that stems from weaker consumer sentiment during the coronavirus-stricken quarter, when total Chinese e-commerce rose just 5.9% or at less than a third of 2019’s pace, according to government data. Jefferies analysts led by Thomas Chong wrote that Alibaba’s guidance was in fact a positive when viewed against an array of uncertainties gripping the post-Covid 19 global economic environment.What Bloomberg Intelligence SaysUser engagement and transaction volume have rebounded in April and May to precrisis levels, which bodes well for normalized sales growth ahead, especially as merchant-support measures are gradually rolled back.\- Vey-Sern Ling and Tiffany Tam, analystsClick here for the research.Rival PDD posted a revenue rise of 44% on Friday, down sharply from 91% in the previous quarter but ahead of expectations. Its sales and marketing expenses jumped 49%. PDD’s shares climbed 15% Friday.Alibaba’s March-quarter net income was 3.2 billion yuan, down 88% from a year ago when it booked an 18.7 billion yuan one-time gain on investments. In February, Alibaba declared a waiver of some service fees for merchants struggling financially during the outbreak on its main direct-to-consumer Tmall platform. In April, the company rolled out a new 10-billion-yuan subsidy program for Tmall users to buy electronics, encroaching on JD.com’s traditional turf. These initiatives may further compress margins for the June quarter.“The challenging part is for them to achieve the same amount of growth this year,” said Steven Zhu, a Shanghai-based analyst with Pacific Epoch. “Just because they are too big, for the same amount of growth, they need to spend much more effort.”But executives were confident in a gradual e-commerce recovery over the year. Beyond its main business, younger divisions such as its cloud computing arm should buoy the bottom line. That division’s revenue jumped 58% in the quarter.“Despite a challenging quarter due to reduced economic activities in light of the COVID-19 pandemic in China, we achieved our annual revenue guidance,” Wu said in a statement. “Although the pandemic negatively impacted most of our domestic core commerce businesses starting in late January, we have seen a steady recovery since March.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    from Yahoo Finance https://ift.tt/2A2eqLU

  • Hong Kong Protesters Clash With Police After China Tightens Grip

    Hong Kong Protesters Clash With Police After China Tightens GripMay.24 — Hong Kong protesters battled with riot police in busy downtown areas on Sunday, showing their opposition toward China’s dramatic move to crack down on dissent in the biggest demonstration since the coronavirus swept through the city in January. Stephen Engle reports on “Bloomberg Daybreak: Australia.”

    from Yahoo Finance https://ift.tt/2LWLSWU

  • Apple China Sales On Recovery Path In April, iPhone Sales Jump 160% – Report

    Apple China Sales On Recovery Path In April, iPhone Sales Jump 160% – ReportApple Inc.’s (AAPL) China sales continued to recover in April, driven partly by the launch of a cheaper iPhone, CNBC reported.The tech giant sold 3.9 million iPhones in China in April, reflecting a 160% surge from March figures, when it sold 1.5 million smartphones, the Shanghai-based market research firm CINNO Research told CNBC.The signs of a recovery path since February comes as the world’s second largest economy slowly reopens again after the coronavirus pandemic forced store closures earlier this year that led to sales declines. China iPhone sales slumped 60% in February year-on-year. Since mid-March, all stores in China have reopened.Apple, which launched its second-generation iPhone SE in mid-April, started to sell the device in China later that month. It starts at 3,299 yuan ($464) in the mainland. iPhone SE accounted for 24% of all of Apple’s 3.9 million iPhone sales in April, according to CINNO Research.In April, overall smartphone shipments in China rose over 94% to 40.8 million compared with the previous month, according to state-backed think tank, China Academy of Information and Communications Technology.Five-star analyst Daniel Ives at Wedbush, who has a Buy rating on the stock with a $350 price target, sees a seminal moment for Apple in China with pressure on both ends of the spectrum from a supply and demand perspective amid renewed tensions between the U.S. and China.The recent Department of Commerce ban on Huawei, preventing it from purchasing semiconductors from U.S. companies, has ignited fears of retaliatory moves against companies such as Apple.“On the demand story, a relative bright spot during this COVID-19 Category 5 storm remains China which represents a growth linchpin region for the company representing roughly 20% of all iPhone upgrades over the next 12 to 18 months with our estimation that 60 million to 70 million iPhones in China are currently in the window of opportunity,” Ives wrote in a note to investors. “From a supply chain perspective we believe Apple would only be able to move 5%-7% of iPhone production to India/ Vietnam over the 18 to 24 months if the China situation/tensions spirals down a more negative and nasty path over the coming months.”Ives believes though that “while uncertainty will add to an already worrisome near-term situation around the global demand picture for Apple, the fundamental impact on iPhone production and the potential backlash in the region thus far is more bark than bite”.Turning now to the rest of Wall Street, analysts have a bullish outlook on Apple’s stock. The Strong Buy consensus is backed up by 27 Buys with the rest split between 4 Holds and 1 Sell. The $318.93 average price target indicates shares are fully priced (See Apple stock analysis on TipRanks).Related News: Apple To Reopen More Than 25 U.S. Stores This Week Google, Apple Roll Out Coronavirus Contact Tracing Technology Apple is Said to Snap Up Startup NextVR For Virtual Reality Content; Top Analyst Sees Buying Opportunity More recent articles from Smarter Analyst: * Vermilion Energy CEO Steps Down With Immediate Effect * American Airlines and Others Given Go-Ahead to Reduce Route Coverage * Facebook Workplace Hits 5 Million Paid Users As Remote Work Demand Rises * NYSE to Reopen Its Trading Floor on Tuesday

    from Yahoo Finance https://ift.tt/2LY5Os8

  • BlackRock Investment Institute Is ‘Underweight’ Japan Stocks

    BlackRock Investment Institute Is 'Underweight' Japan StocksMay.25 — Ben Powell, chief APAC investment strategist, at BlackRock Investment Institute, shares his views on the region’s markets and global policies. He speaks with Haslinda Amin and Tom Mackenzie on “Bloomberg Markets: Asia.”

    from Yahoo Finance https://ift.tt/2ARb7ay

  • Bayer says it makes progress in settlement talks over weedkiller

    Bayer says it makes progress in settlement talks over weedkillerBayer said on Monday it had made progress seeking a settlement over claims its glyphosate-based Roundup weedkiller causes cancer, after Bloomberg reported the company reached a verbal agreement on about 50,000 to 85,000 cases. In April, Bayer’s management regained shareholder support for its handling of the litigation process. Bloomberg cited people familiar with the negotiations as saying that the deals have yet to be signed and Bayer is likely to announce the settlements in June.

    from Yahoo Finance https://ift.tt/2TBPku7

  • 3 exciting small cap ASX healthcare shares to watch

    asx healthcare shares

    Due to new technologies and favourable industry tailwinds, I think there are a number of small cap ASX healthcare shares which have the potential to grow materially over the next 10 years.

    Three small cap healthcare shares to add to your watchlist right now are listed below. Here’s why I think they are worth watching:

    Alcidion Group Ltd (ASX: ALC)

    The first small cap ASX healthcare share to watch is Alcidion. It is a health informatics company aiming to transform healthcare with smart, intuitive technology solutions. The company has a growing portfolio of software products and services that support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient outcomes. At present its software is in 215 hospitals, 42 healthcare organisations, and on 30,000 beds. I expect this to increase strongly in the coming years and drive strong sales growth.

    Medadvisor Ltd (ASX: MDR)

    Another ASX healthcare share to watch is Medadvisor. It is a growing software systems developer with a focus on addressing gaps in personal medication adherence. The company provides software that connects to pharmacy dispensing systems to automatically retrieve medication records. It also comes with an intelligent training, information, and reminder system to ensure correct and reliable medication use. In addition to this, the company is rolling out a medicine delivery service and a telehealth solution. The latter looks set to benefit from the rapid adoption of telehealth technology following the pandemic.

    Volpara Health Technologies Ltd (ASX: VHT)

    Another small cap ASX healthcare share which I believe has significant potential is Volpara. Its software leverages artificial intelligence imaging algorithms to assist with the early detection of breast cancer. It has been growing its market share in North America at an exceptionally strong rate. This led to the company recently reporting a 172% increase in annual recurring revenue (ARR) to NZ$18 million. The good news is that this is still only scratching at the surface of an estimated US$750 million ARR opportunity in breast cancer screening.

    And here are more top shares which analysts have just given buy ratings to. All five recommendations below look dirt cheap after the crash…

    5 cheap stocks that could be the biggest winners of the stock market crash

    Investing expert Scott Phillips has just named what he believes are the 5 cheapest and best stocks to buy right now.

    Courtesy of the crashing stock market, these 5 companies are suddenly trading at significant discounts to their recent highs… creating what could be incredible opportunities for bargain-hungry investors.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares to buy now… before the next stock market rally.

    See the 5 stocks

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Alcidion Group Ltd and MedAdvisor. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia has recommended Alcidion Group Ltd and MedAdvisor. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 3 exciting small cap ASX healthcare shares to watch appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2ziOaNl

  • CSL shares have underperformed the ASX 200 over the past month. What’s going on?

    Man asking financial questions

    The CSL Limited (ASX: CSL) share price has done the unthinkable and actually underperformed the broader S&P/ASX 200 Index (ASX: XJO) over the past month.

    To be frank, CSL shares normally beat the pants off the market. It managed to do this both in the 2016–2020 bull market and in the short-but-sharp bear market we saw in February and March of this year.

    But since mid-April, CSL shares have actually fallen around 10%, whilst the ASX 200 has rallied around 7% over the same period.

    What’s going on?

    Has CSL lost its magic?

    Well, in my opinion, the recent underperformance of CSL shares has nothing to do with the company itself. CSL hasn’t yet told the markets if it expects any material hit to revenue or earnings as a result of the coronavirus pandemic (apart from disruption to plasma collections). CSL isn’t actively joining the race for a COVID-19 vaccine, but (as Fool contributor Nikhil Gangaram pointed out today) the company is working on antibody-based medicines that will allow patients to recover faster without the use of a ventilator.

    We do know that CSL has obtained additional capital (US$750 million at 2.68%) through the bond market recently, but again, this doesn’t indicate anything of significance for investors in my view.

    So no, I don’t think CSL has lost its magic.

    Instead, I view the pullback in the CSL share price as a sign that investors might have got a little ahead of themselves in April.

    CSL shares reached lows of $270.88 in March, but by 9 April, CSL was back to $329 a share, just below the all-time high of $342.75 that we saw in February.

    Given what’s going on in the global economy, it’s possible investors decided this run-up was a little optimistic, and that’s why we are seeing a more subdued CSL share price in recent weeks.

    Are CSL shares a buy today?

    Although I’ve long thought CSL is a top company, it’s also a little too highly priced for me to consider a buy today. Even on today’s share price of $298.27, the company is still asking a price-to-earnings (P/E) ratio of 44.28. That’s a fairly high number for the ASX’s largest company, and one I don’t think is entirely justified by CSL’s future growth prospects.

    I might be waiting a while, but CSL is still not in the buy zone for me, despite its resilience and quality as a business.

    Instead, I’m looking at these 5 shares! Check them out in the report below!

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading 40% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    YES! SEND ME THE FREE REPORT!

    More reading

    Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post CSL shares have underperformed the ASX 200 over the past month. What’s going on? appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2WXg0aQ